Norgine completes acquisition of Theravia

15-Aug-2025

Symbol image

AI-generated image

Revolutionize your production: real-time Raman analysis for maximum efficiency

Efficient inline analysis for liquids and solids

User-friendly software for effortless Design of Experiments (DoE)

Norgine announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specializing in therapies for patients with rare and serious diseases. The completion of this acquisition is an important step for Norgine towards its goal of bringing life-changing medicines to patients with high unmet medical needs.

Upon completion of the transaction, Norgine will initiate a structured integration process to align operations, systems and teams.

"We are delighted to have successfully completed this acquisition as the integration of Theravia into our business further strengthens our expertise in rare diseases and expands our portfolio in this area," said Janneke van der Kamp, Chief Executive Officer of Norgine. "This acquisition is an important step in our growth strategy. With our strong focus on expanding the product range for patients in areas of high unmet medical need in Europe and Australia/New Zealand, we are well positioned to ensure Theravia's medicines reach more patients."

As a result of the acquisition, Theravia is now a wholly owned subsidiary of Norgine.

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

https://www.bionity.com/en/news/1186934/norgine-completes-acquisition-of-theravia.html